Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Neuroscience Right
  3. Reyvow (lasmiditan) tablets CV Right
  4. How is Reyvow® (lasmiditan) absorbed and distributed?
Search Reyvow (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Reyvow ® (lasmiditan) tablets CV

50 mg, 100 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

How is Reyvow® (lasmiditan) absorbed and distributed?

Reyvow (lasmiditan) is rapidly absorbed after oral administration. In patients with migraine, absorption or pharmacokinetics of lasmiditan was similar during a migraine attack or during the interictal period.

US_cFAQ_LAS003_ABSORPTION_DISTRIBUTION
US_cFAQ_LAS003_ABSORPTION_DISTRIBUTION
en-US

Pharmacokinetic Properties

Absorption

Following oral administration, lasmiditan is rapidly absorbed with a median Tmax of 1.8 hours.1

In patients with migraine, the absorption or pharmacokinetics of lasmiditan was not different during a migraine attack versus during the interictal period.1

The oral bioavailability over the clinical dose range of 50 mg to 200 mg is predicted to be 50% to 58%, based on the results from a population pharmacokinetics analysis.2

Effect of Food on Absorption

Lasmiditan may be taken with or without food as administration with meals was not associated with a clinically relevant effect on exposure to lasmiditan.1

Coadministration of lasmiditan with a high-fat meal

  • increased mean lasmiditan Cmax and AUC values by 22% and 19%, respectively, and
  • delayed the median Tmax by 1 hour.1

Distribution

The human plasma protein binding of lasmiditan is

  • approximately 55% to 60%, and
  • independent of concentration between 15 and 500 ng/mL.1

Enclosed Prescribing Information

REYVOW® (lasmiditan) tablets, for oral use, CV, Lilly

References

1Reyvow [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

2Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

AUC = area under the curve

Cmax = maximum observed drug concentration

Tmax = time of maximum observed drug concentration

Date of Last Review: August 10, 2021

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly